McLaughlin joins YorLabs as president, CEO

AuntMinnie.com staff writers
May 4, 2022
2019 12 19 00 53 5252 Hands Shaking Deal 400

Ultrasound industry veteran Glen McLaughlin, PhD, has joined image-guided therapy developer YorLabs as president and CEO.

Previously with ultrasound developer Mindray, McLaughlin is best known as the founder of Zonare Medical Systems, which was founded in 1999 and was acquired by Mindray in 2013.

McLaughlin held a variety of positions at Zonare, including chief technology officer and vice president of product marketing and engineering. At Mindray, he was president of the company's Innovation Center in Silicon Valley and served as vice president of global corporate partnerships and chief product officer of worldwide ultrasound production.

McLaughlin rounds out the executive suite at YorLabs, which includes Anshumali Roy as chief technology officer and William "Bill" Starling as named chairman of the board.

YorLabs is developing intracardiac image-guided therapy technology that's designed to be more cost-effective and improve workflow.

Latest in Ultrasound
Ovarian Cancer Social
Nomogram model predicts malignancy risk in ovarian masses
November 19, 2024
Heart Plaque
AI-enabled CCTA on par with IVUS for plaque quantification
November 14, 2024
Emergency 400
Ultrasound-guided nerve blocks safe for emergency pain management
November 13, 2024
Thyroid Cancer
Thermal ablation effective long term in patients with thyroid cancer
November 7, 2024
Related Stories
2016 08 24 09 43 13 537 Hands Shaking V3 400
Ultrasound
YorLabs taps Marcotte as new CFO
2020 02 21 17 18 9566 Business Handshake Woman 400
Ultrasound
YorLabs adds new senior VP
2020 02 21 17 18 9566 Business Handshake Woman 400
Ultrasound
YorLabs names new chief commercialization officer
2019 12 19 00 53 5252 Hands Shaking Deal 400
Advanced Visualization
YorLabs appoints new board chairman
More in Ultrasound
Nomogram model predicts malignancy risk in ovarian masses
By Amerigo Allegretto
A nomogram model based on O-RADS ultrasound findings and clinical and lab indicators can predict malignancy risk in adnexal cystic-solid masses.
November 19, 2024
Ovarian Cancer Social
AI-enabled CCTA on par with IVUS for plaque quantification
By Kate Madden Yee
An AI-powered automated plaque quantification tool for coronary CT angiography (CCTA) performs on par with intravascular ultrasound (IVUS) for quantifying heart plaque volume and characterizing plaque.
November 14, 2024
Heart Plaque
Ultrasound-guided nerve blocks safe for emergency pain management
By Amerigo Allegretto
Ultrasound-guided nerve blocks (UGNBs) performed by emergency clinicians could be safe for pain management.
November 13, 2024
Emergency 400
Thermal ablation effective long term in patients with thyroid cancer
By Will Morton
Outcomes over 10 years suggest that image-guided thermal ablation is a safe and effective option for patients with papillary thyroid carcinoma.
November 7, 2024
Thyroid Cancer
Could cranial ultrasound sub for brain MRI in imaging infants?
By Amerigo Allegretto
Cranial ultrasound could have utility for imaging infants with hypoxic-ischemic encephalopathy.
November 6, 2024
Baby Bottle
Ultrasound nonmass breast lesion features may signal malignancy
By Amerigo Allegretto
Some nonmass breast lesion characteristics on ultrasound exams can be considered suspicious for malignancy at screening ultrasound.
November 5, 2024
Images depict a 43-year-old woman with a malignant nonmass lesion that was diagnosed as microinvasive ductal carcinoma. (A) Transverse and (B) longitudinal ultrasound images show a hypoechoic nonmass lesion (solid arrows) with segmental distribution in the left breast. The lesion has associated calcifications (dashed arrows in A). (C) Longitudinal color Doppler ultrasound image shows high vascularity. (D) Magnified image in the mediolateral oblique view from screening mammography shows grouped calcifications (arrows), which are considered a mammographic correlate of the ultrasound-detected nonmass lesion (A radiopaque marker attached to the skin is visible in the image because the mammographic exam was performed after screening breast ultrasound). Ultrasound-guided core needle biopsy and pathologic examination revealed ductal carcinoma in situ, but the lesion was upgraded to microinvasive ductal carcinoma at subsequent surgery (2.5-cm ductal carcinoma in situ, histologic grade II, estrogen receptor-positive, progesterone receptor-positive, human epidermal growth factor receptor type 2-negative).
ChatGPT demonstrates mixed results in assigning BI-RADS categories
By Amerigo Allegretto
ChatGPT achieves modest accuracy when assigning BI-RADS scores for mammograms and breast ultrasound exams.
November 1, 2024
Chat Gpt 400
ABUS screening improves breast cancer screening in low-resource areas
By Amerigo Allegretto
Automated breast ultrasound (ABUS) with remote reading may improve access to breast cancer screening and early detection in low-resource settings.
October 29, 2024
Ultrasound Breast 400
Ukraine's top pediatric hospital rebuilds after bomb attack
By Philip Ward
Radiology staff at the Ohmatdyt Children's Hospital in Kyiv are making steady progress with their plan to restore normal service after a devastating missile attack.
October 25, 2024
Thanks to the support of the global imaging community, radiology staff at the Ohmatdyt can now look forward to restoring normal service.
CNN models using ultrasound images detect pancreatic neoplasms
By Amerigo Allegretto
A deep-learning method using endoscopic ultrasound images could detect pancreatic neuroendocrine neoplasms.
October 18, 2024
Ultrasound Scanner Computerized 400
Ultrasound method detects cellular rejection in liver transplant cases
By Amerigo Allegretto
An ultrasound measurement technique could detect and stage acute cellular rejection in liver transplant patients.
October 16, 2024
Ultrasound Diagnostic Control Panel
Could elastography replace conventional ultrasound-guided FNAC?
By Amerigo Allegretto
Strain elastography does not have additional benefits over conventional elastography-guided FNAC for diagnosing malignancy in thyroid nodules.
October 15, 2024
Images depict a 43-year-old woman with a solitary left-sided thyroid nodule classified at gray-scale ultrasound as category U3, upgraded to category U4 at strain elastography, and classified as category Thy4 at cytopathologic examination. Subsequent surgical histopathologic examination confirmed papillary cell carcinoma. (A) Longitudinal view of the left thyroid lobe demonstrates the low reflective nodule (between arrows) measuring 13 × 12 × 11 mm (not shown) and with a halo. (B) A longitudinal image with side-by-side visualization of the nodule (arrow) at gray scale (left) and strain elastography (right). The nodule is predominantly blue, indicating increased stiffness. (C) A longitudinal view shows the needle (arrows) within the stiffer aspect of the nodule for cytology sampling. U and Thy categories are according to British Thyroid Association system. Image courtesy of the RSNA.
Page 1 of 512
Next Page